Summary
Oligonucleotides, including antisense oligos, CpG oligos, and siRNAs, are molecularly targeted agents with great potential therapeutic applications. A major obstacle for clinical application of these novel agents is the lack of effective in vivo delivery systems. Investigators at OSU College of Pharmacy and the Center for Affordable Nanoengineering of Polymeric Biomedical Devices (CANPBD) have developed novel nanoparticle formulations that have shown excellent activity in enhancing the cellular delivery of oligonucleotides by converting these into nanomedicines. Cancer and leukemia cell-targeted nanoparticles of novel compositions have been developed to achieve tissue-specific delivery. The novel nanoparticle delivery technology will enable clinical application of a wide range of oligonucleotide therapeutics for treatment of cancer and leukemia.
Feb. 1, 2012
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium